Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate

Calcified Tissue International

Volumn 87, Issue 4, 2010, Pages 305-313

  Miller, Paul D ^a   Delmas, Pierre D ^b   Huss, Hermann ^c   Patel, Katie M ^d   Schimmer, Ralph C ^e   Adami, Silvano ^f   Recker, Robert R ^g  

^a University of Colorado Health Sciences Center   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c BAYER AG   (Germany)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF VERONA   (Italy)

^g CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone mineral density; Fracture; Ibandronate; Surrogate marker

Indexed keywords

CALCIUM; IBANDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; HIP; HUMAN; LUMBAR SPINE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HIP JOINT; HUMANS; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 77957703072     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9403-y     Document Type: Article

References (30)

1. XG Cheng G Lowet S Boonen PH Nicholson G Van der Perre J Dequeker 1998 Prediction of vertebral and femoral strength in vitro by bone mineral density measured at different skeletal sites J Bone Miner Res 13 1439 1443 10.1359/jbmr.1998.13.9.1439 1:STN:280:DyaK1cvgvVyqtA%3D%3D 10.1359/jbmr.1998.13. 9.1439 9738516 (Pubitemid 28418910)
2. SR Cummings DM Black MC Nevitt W Browner J Cauley K Ensrud J Scott TM Vogt 1993 Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group Lancet 341 72 75 10.1016/0140-6736(93)92555-8 1:STN:280:DyaK3s7hs1GisA%3D%3D 10.1016/0140- 6736(93)92555-8 8093403 (Pubitemid 23028113)
3. LJ Melton 3rd EJ Atkinson WM O'Fallon HW Wahner BL Riggs 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites J Bone Miner Res 8 1227 1233 10.1002/jbmr.5650081010 10.1002/jbmr.5650081010 8256660
4. SR Cummings DB Karpf F Harris HK Genant K Ensrud AZ LaCroix DM Black 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289 1:CAS:528:DC%2BD38XhvVWkurk%3D 10.1016/S0002-9343(01)01124-X 11893367 (Pubitemid 34219441)
5. MC Hochberg S Greenspan RD Wasnich P Miller DE Thompson PD Ross 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592 1:CAS:528:DC%2BD38XivFKlt7k%3D 10.1210/jc.87.4.1586 11932287 (Pubitemid 34615244)
6. PD Miller 2005 Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction Curr Osteoporos Rep 3 103 110 10.1007/s11914-005-0018-6 16131430
7. PD Miller MC Hochberg LE Wehren PD Ross RD Wasnich 2005 How useful are measures of BMD and bone turnover? Curr Med Res Opin 21 545 554 10.1185/030079905X41390 10.1185/030079905X41390 15899103 (Pubitemid 40676106)
8. RD Wasnich PD Miller 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density J Clin Endocrinol Metab 85 231 236 1:STN:280:DC%2BD3c%2Fpslymug%3D%3D 10.1210/jc.85.1.231 10634392 (Pubitemid 32268819)
9. NB Watts C Cooper R Lindsay R Eastell MD Manhart IP Barton 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 261 10.1385/JCD:7:3:255 10.1385/JCD:7:3:255 15319494 (Pubitemid 39178892)
10. P Chen PD Miller PD Delmas DA Misurski JH Krege 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis J Bone Miner Res 21 1785 1790 10.1359/JBMR.060802 1:CAS:528:DC%2BD28Xht1ert7jL 10.1359/jbmr.060802 17002571 (Pubitemid 46141234)
11. NB Watts PD Miller LA Kohlmeier A Sebba P Chen M Wong K Krohn 2009 Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment J Bone Miner Res 24 1125 1131 10.1359/JBMR.081256 1:CAS:528:DC%2BD1MXmvFyjt70%3D 10.1359/jbmr.081256 19113918
12. PD Delmas Z Li C Cooper 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses J Bone Miner Res 19 330 337 10.1359/JBMR.0301228 1:CAS:528:DC%2BD2cXhs1elsrg%3D 10.1359/JBMR.0301228 14969404 (Pubitemid 38116748)
13. PD Delmas E Seeman 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy Bone 34 599 604 10.1016/j.bone.2003.12.022 1:CAS:528: DC%2BD2cXisF2ntL4%3D 10.1016/j.bone.2003.12.022 15050889 (Pubitemid 38393794)
14. Z Li AA Chines MP Meredith 2004 Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 4 64 74 1:CAS:528:DC%2BD2cXosF2qu74%3D 15615079
15. S Sarkar JY Reginster GG Crans A Diez-Perez KV Pinette PD Delmas 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Miner Res 19 394 401 10.1359/JBMR.0301243 10.1359/JBMR.0301243 15040827 (Pubitemid 38787394)
16. NB Watts P Geusens IP Barton D Felsenberg 2005 Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD J Bone Miner Res 20 2097 2104 10.1359/JBMR.050814 10.1359/JBMR.050814 16294263 (Pubitemid 41698773)
17. LS Freedman BI Graubard A Schatzkin 1992 Statistical validation of intermediate endpoints for chronic diseases Stat Med 11 167 178 10.1002/sim.4780110204 1:STN:280:DyaK383ltlyrtQ%3D%3D 10.1002/sim.4780110204 1579756
18. J Shih DC Bauer J Orloff T Capizzi D Thompson L Oppenheimer PD Ross 2002 Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors Osteoporos Int 13 Suppl 3 S38 S39 (abstract P79)
19. R Russell N Watts F Ebetino MJ Rogers 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical safety Osteoporos Int 19 733 759 10.1007/s00198-007-0540-8 1:CAS:528:DC%2BD1cXltFyjurw%3D 10.1007/s00198-007-0540-8 18214569
20. C Leu E Luegmayr L Freedman GA Rodan AA Reszka 2006 Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy Bone 38 628 636 10.1016/j.bone.2005.07.023 1:CAS:528: DC%2BD28XjvFSjtr8%3D 10.1016/j.bone.2005.07.023 16185944
21. GH Nancollas R Tang RJ Phipps Z Henneman S Guide W Wu A Mangood RGG Russell FH Ebetino 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 617 627 10.1016/j.bone.2005.05.003 1:CAS:528:DC%2BD28XjvFSjtr4%3D 10.1016/j.bone.2005. 05.003 16046206
22. CH Chesnut III A Skag C Christiansen R Recker JA Stakkestad A Hoiseth D Felsenberg H Huss J Gilbride RC Schimmer PD Delmas for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America, Europe (BONE) 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 10.1359/JBMR.040325 1:CAS:528:DC%2BD2cXntFGqurw%3D 10.1359/JBMR.040325 (Pubitemid 41094364)
23. PD Delmas RR Recker CH Chesnut III A Skag JA Stakkestad R Emkey J Gilbride RC Schimmer C Christiansen for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America, Europe (BONE) 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15 792 798 10.1007/s00198-004-1602-9 1:CAS:528:DC%2BD2cXnsVCit7g%3D 10.1007/s00198-004-1602-9 15071723 (Pubitemid 39361949)
24. PD Miller MR McClung L Macovei JA Stakkestad M Luckey B Bonvoisin JY Reginster RR Recker C Hughes EM Lewiecki D Felsenberg PD Delmas DL Kendler ML Bolognese N Mairon C Cooper 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 1315 1322 10.1359/JBMR.050313 1:CAS:528:DC%2BD2MXovV2msrk%3D 10.1359/JBMR.050313 16007327 (Pubitemid 41033514)
25. R Recker JA Stakkestad CH Chesnut III C Christiansen A Skag A Hoiseth M Ettinger P Mahoney RC Schimmer PD Delmas 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis Bone 34 890 899 10.1016/j.bone.2004.01.008 1:CAS:528:DC%2BD2cXjs1WktrY%3D 10.1016/j.bone.2004.01.008 15121021 (Pubitemid 38581135)
26. SE Papapoulos RC Schimmer 2007 Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate Ann Rheum Dis 66 853 858 1:CAS:528: DC%2BD2sXotlSit7w%3D 17277001
27. RL Prentice 1989 Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 431 440 10.1002/sim.4780080407 1:STN:280:DyaL1M3ms1aktg%3D%3D 10.1002/sim.4780080407 2727467
28. ® assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int. doi: 10.1007/s00198-009-0975-1
29. JA Kanis O Johnell A Odena H Johansson E McCloskey 2008 FRAX™ and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 397 10.1007/s00198-007-0543-5 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D 10.1007/s00198-007-0543-5 18292978
30. Sebba A, Emkey R, Blumentals WA, Sambrook P (2007) Relationship between increasing annual cumulative exposure to ibandronate, increases in BMD and reductions in clinical fractures. J Bone Miner Res 22(Suppl 1):S454 (abstract W365)